The Role of Neoadjuvant Chemotherapy in Patients With Resectable Malignant Pleural Mesothelioma—An Institutional and National Analysis
Abstract
There is no standard of care with respect to the use of neoadjuvant chemotherapy (NAC) in resectable malignant pleural mesothelioma (MPM). We performed an intention-to-treat analysis with data from a single institution and the National Cancer Database (NCDB) to identify whether the use of NAC impacts survival in resectable MPM.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 03, 2020
- Source ID
- 10.1093/jnci/djaa002
Entities
People
- Betty C Tong
- Chi-fu Jeffrey Yang
- David H. Harpole
- Muath Bishawi
- Oliver K Jawitz
- Soraya L Voigt
- Thomas A D’amico
- Vignesh Raman
Organizations
- Duke University
- National Institutes of Health
- Stanford University
- United States Department of Defense